Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Pharmaceutical composition for preventing and/or treating diabetes mellitus

A technology of diabetes and composition, which is applied in the direction of drug combination, metabolic disease, medical formula, etc., can solve the problems of unstable quality control of traditional Chinese medicine, processing of crude preparations, unknown active ingredients, etc., and achieve the protection of islet cells, great application prospects, Obvious effect of hypoglycemia

Active Publication Date: 2015-01-14
正北芪产业科技(深圳)有限公司
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no ideal traditional Chinese medicine monomer or traditional Chinese medicine compound that can replace the classic oral hypoglycemic western medicine to stably and effectively lower blood sugar.
In addition, most of these traditional Chinese medicines on the market are used together with other traditional Chinese medicines, which makes the quality control of Chinese medicines relatively unstable and the reproducibility of curative effects is poor.
At present, there are many kinds of patents on the treatment of diabetes with Astragalus, Hawthorn and other traditional Chinese medicines, but most of the crude drugs are not clear, or are low-level crude preparations, and it is impossible to effectively control the quality standards of their production processes, and their specific active ingredients are not known. Why, thus limiting its further application, it is also difficult to form a large-scale production effect and connect with the international market, and it is also difficult to meet the actual needs of the increasing number of diabetic patients at home and abroad

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for preventing and/or treating diabetes mellitus
  • Pharmaceutical composition for preventing and/or treating diabetes mellitus
  • Pharmaceutical composition for preventing and/or treating diabetes mellitus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Example 1. Preparation of drugs for treating diabetes

[0045] Astragalus polysaccharide is prepared by using Astragalus root as raw material through conventional extraction process and spray drying. The content of polysaccharide is 50% after testing. The specific method is as follows: Take 500g of Astragalus decoction pieces (Shenzhen Lifeng Pharmaceutical Company, batch number 111128), add 10 times the amount of distilled water to reflux and extract for 2 hours, filter, add 10 times the amount of water to the filter residue and extract again for 1 hour, and filter. The two filtrates were combined and concentrated to 500ml, added with 3 times volume fraction of 95% ethanol solution, allowed to stand overnight at low temperature, centrifuged, filtered with suction, and dried under vacuum to obtain astragalus polysaccharide.

[0046] Hawthorn flavonoids are prepared from hawthorn fruit by conventional extraction process and spray drying. The content of flavonoids is 30%. The...

Embodiment 2

[0047] Example 2. The effect of different drug ratios on oral glucose tolerance test in diabetic mice

[0048] 1. Making of NIH mouse diabetes model

[0049] NIH male mice (about 20g) were fasted for 24 hours and then injected with 100mg / kg streptozotocin (Streptozotocin, American Sigma company) once (streptozotocin was freshly prepared with citrate buffer in an ice bath). Prepared (0.1M, pH4.5), injection completed within 5 minutes). After 10 days, the mice with steadily elevated blood glucose (blood glucose above 11.1 mmol / L) are NIH mouse diabetes models.

[0050] 2. Oral glucose tolerance test

[0051] After fasting overnight, the diabetic mice were given 2.5g / kg glucose solution by gavage. Blood was taken from the mouse orbit at time 0, 0.5, 1 and 2 hours, and the serum was centrifuged to detect the glucose concentration. Compare the blood glucose and blood glucose at each time point. The change in the area under the blood glucose-time curve.

[0052] In the diabetic mouse model...

Embodiment 3

[0054] Example 3. Pharmacodynamics of drugs for treating diabetes

[0055] 1. Making of NIH mouse diabetes model

[0056] The same as in Example 2.

[0057] 2. Administration of NIH mouse diabetes model

[0058] After the diabetes model was successfully screened, grouping (n=10) was performed, and the following drug components were administered by gavage for four consecutive weeks.

[0059] Astragalus polysaccharide and hawthorn flavone mixed treatment group (HS): In the NIH mouse diabetes model, astragalus polysaccharide and hawthorn flavone were mixed at a net content of 1:1, and the net content was 200mg / kg / day for intragastric administration. medicine.

[0060] Astragalus polysaccharide single treatment group (H): In NIH mouse diabetes model, astragalus polysaccharide was administered by gavage at a net content of 200 mg / kg / day.

[0061] Hawthorn flavonoids alone treatment group (S): In the NIH mouse diabetes model, hawthorn flavonoids were administered intragastrically at a net cont...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for preventing and / or treating diabetes mellitus. The pharmaceutical composition is prepared from hawthorn flavone and astragalus polysaccharide, wherein the mass ratio of the hawthorn flavone to the astragalus polysaccharide is (4:1) to (1:2), preferably (2:1) to (1:2). A pharmacodynamic test shows that the pharmaceutical composition has significant effects of reducing fasting blood-glucose and postprandial blood sugar of the diabetes mellitus, improving insulin sensitivity, improving symptoms of diabetes and restraining disturbance of carbohydrate metabolism caused by fatty food; the action mechanism is related to protection and repair of an islet cell function while the hawthorn flavones and the astragalus polysaccharide can be independently dosed; no ideal antidiabetic effect is displayed.

Description

Technical field [0001] The invention relates to a pharmaceutical composition for preventing and / or treating diabetes. Background technique [0002] Diabetes is a chronic disorder of glucose metabolism that seriously affects human health. According to the 2010 National Diabetes Special Survey, the prevalence of adult diabetes in my country is 9.7%, 10.6% for men and 8.8% for women. Especially in recent years, the incidence of diabetes has been rising rapidly with the improvement of people's living standards. my country is in a period of high incidence of diabetes, and diabetes has become one of the major public health problems in my country. Although there are drugs that effectively control blood sugar in diabetes, most of them still treat the symptoms rather than the root cause. [0003] At present, the mechanism of action of hypoglycemic drugs is mainly manifested in the following aspects: 1. To supplement insulin levels, such as insulin injection preparations; 2. To increase pa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/734A61P3/10A61K31/715
Inventor 谢伟东张雅鸥许乃寒
Owner 正北芪产业科技(深圳)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com